This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bert, F. Articles by Branger, C. Search for Related Content PubMed PubMed Citation Articles by Bert, F. Articles by Branger, C.

Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate Staphylococcus aureus in Liver Transplant Recipients

Departments of Microbiology,¹ Hepatology,² Anesthesiology, Hospital Beaujon, Clichy, France³

Received 24 January 2003/ Returned for modification 12 March 2003/ Accepted 5 August 2003

We investigated the prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) isolates in 48 liver transplant recipients infected or colonized with methicillin-resistant S. aureus over a 5-year period. Strains were screened for hGISA on Mueller-Hinton agar containing 5 mg of teicoplanin per liter. Heterogeneous glycopeptide resistance was confirmed by the E-test method with a dense inoculum and a simplified method of population analysis. hGISA strains were found in 13 (27%) of the 48 patients studied. Eleven of the 13 strains shared a common multiresistant phenotype with homogeneous methicillin resistance and gentamicin resistance, and they were closely related according to the results of pulsed-field gel electrophoresis. Only 2 of the 13 patients infected or colonized with hGISA strains had previously received glycopeptide therapy. Most patients were successfully treated with vancomycin, but one patient who failed to respond to vancomycin subsequently died. These results suggest that the high prevalence of hGISA among our patients was due to the clonal spread of a multiresistant strain.

This article has been cited by other articles:

• Rose, W. E., Leonard, S. N., Rossi, K. L., Kaatz, G. W., Rybak, M. J. (2008). Relationships between vancomycin pharmacodynamics and the emergence of vancomycin-intermediate Staphylococcus aureus (VISA) from heterogeneous VISA in an in vitro pharmacodynamic model. J Antimicrob Chemother 0: dkn037v1-6 [Abstract] [Full Text]  
• Garnier, F., Chainier, D., Walsh, T., Karlsson, A., Bolmstrom, A., Grelaud, C., Mounier, M., Denis, F., Ploy, M.-C. (2006). A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 57: 146-149 [Abstract] [Full Text]  
• Song, J.-H., Hiramatsu, K., Suh, J. Y., Ko, K. S., Ito, T., Kapi, M., Kiem, S., Kim, Y.-S., Oh, W. S., Peck, K. R., Lee, N. Y., and the Asian Network for Surveillance of Resistan, (2004). Emergence in Asian Countries of Staphylococcus aureus with Reduced Susceptibility to Vancomycin. Antimicrob. Agents Chemother. 48: 4926-4928 [Abstract] [Full Text]  
• Huang, V., Brown, W. J., Rybak, M. J. (2004). In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci. Antimicrob. Agents Chemother. 48: 2719-2723 [Abstract] [Full Text]